26 min
Drug Development in Obesity Back Bay Life Science Report
-
- Medicine
Guests: Pete Bak and Christian Thienel
Length: 27 minutes
In this episode of The Life Science Report, Dr. Pete Bak and Back Bay Director, Christian Thienel catch up on the area attracting the most industry interest over the past couple of years: the anti-obesity space.
From big players looking to capitalize on the renewed interest in the obesity space to the staggering success of Novo Nordisk’s and Eli Lilly’s GLP-1 agonists (Ozempic, Wegovy, Mounjaro, and Zepbound) for glycemic control and weight loss, there’s a lot to cover.
Topics in this podcast include:
A brief introduction to glucagon-like peptide 1 (GLP-1) agonistsWhy GLP-1s’ popularity is skyrocketing as treatment for type 2 diabetes and obesityHow amylin and petrelintide (a long-acting amylin analogue) are being newly re-imagined for the obesity space, as well as muscle-targeted approaches like myostatin and activinsWhere BD and investor interest lies as these drugs are expected to have north of $150B in sales annually within the next decadeWhat’s happening in early to late-stage drug developmentWhat the future holds for this sector, possibly to include cannabinoid one receptor inverse agonists and mitochondrial targets for metabolic disease
As always, thank you for joining us. Did you know we welcome listener questions? If there any areas you’d like us to explore further in metabolic disease and obesity, please let us know. Submit your questions here. Our Nordic-American Healthcare Conference 2025 will feature metabolic track. Learn more: https://nordicamericanhealthcareconference.com/
You can find previous episodes of the podcast here.
Guests: Pete Bak and Christian Thienel
Length: 27 minutes
In this episode of The Life Science Report, Dr. Pete Bak and Back Bay Director, Christian Thienel catch up on the area attracting the most industry interest over the past couple of years: the anti-obesity space.
From big players looking to capitalize on the renewed interest in the obesity space to the staggering success of Novo Nordisk’s and Eli Lilly’s GLP-1 agonists (Ozempic, Wegovy, Mounjaro, and Zepbound) for glycemic control and weight loss, there’s a lot to cover.
Topics in this podcast include:
A brief introduction to glucagon-like peptide 1 (GLP-1) agonistsWhy GLP-1s’ popularity is skyrocketing as treatment for type 2 diabetes and obesityHow amylin and petrelintide (a long-acting amylin analogue) are being newly re-imagined for the obesity space, as well as muscle-targeted approaches like myostatin and activinsWhere BD and investor interest lies as these drugs are expected to have north of $150B in sales annually within the next decadeWhat’s happening in early to late-stage drug developmentWhat the future holds for this sector, possibly to include cannabinoid one receptor inverse agonists and mitochondrial targets for metabolic disease
As always, thank you for joining us. Did you know we welcome listener questions? If there any areas you’d like us to explore further in metabolic disease and obesity, please let us know. Submit your questions here. Our Nordic-American Healthcare Conference 2025 will feature metabolic track. Learn more: https://nordicamericanhealthcareconference.com/
You can find previous episodes of the podcast here.
26 min